Cytokinetics, Incorporated (CYTK) announced positive data from the Phase 1 study of its drug candidate CK-586, a cardiac myosin inhibitor being developed for heart failure with preserved ejection fraction (HFpEF). The study demonstrated safety, tolerability, and favorable pharmacokinetic properties, paving the way for potential once-daily fixed-dose administration in future clinical trials.